-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GXchZZ6kAbJagnDDrrhknzgcS/4I3Ze0igsauHJBrVGZbx+ZtQZT7hi5tWEI0u5S 2zNK3lLHwkNtDD4B5pfL9w== 0001047469-98-034028.txt : 19980910 0001047469-98-034028.hdr.sgml : 19980910 ACCESSION NUMBER: 0001047469-98-034028 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19980909 SROS: NASD GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND L P ET AL GROUP MEMBERS: BVF INC. GROUP MEMBERS: BVF PARTNERS L.P. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: OSI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000729922 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133159796 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13D SEC ACT: SEC FILE NUMBER: 005-37954 FILM NUMBER: 98705727 BUSINESS ADDRESS: STREET 1: 106 CHARLES LINDBERGH BLVD CITY: UNIONDALE STATE: NY ZIP: 11553 BUSINESS PHONE: 5162220023 MAIL ADDRESS: STREET 1: 106 CHARLES LINDBERGH BLVD CITY: UNIONDALE STATE: NY ZIP: 11553-3649 FORMER COMPANY: FORMER CONFORMED NAME: ONCOGENE SCIENCE INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P ET AL CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] IRS NUMBER: 363924731 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET STREET 2: 39TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-288-2395 MAIL ADDRESS: STREET 1: ONE SANSOME STREET STREET 2: 39TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94104 SC 13D 1 SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 --------------- SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (AMENDMENT NO. _____)(1) OSI PHARMACEUTICALS, INC. ------------------------- (Name of Issuer) Common Stock ------------ (Title of Class of Securities) 671040 10 3 ----------- (CUSIP Number) Marc Schneidman BVF Partners L.P. 333 West Wacker Drive, Suite 1600 Chicago, Illinois 60606 (415) 288-2396 -------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) September 8, 1998 ----------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box / /. NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. SEE Rule 13d-1(a) for other parties to whom copies are to be sent. (Continued on following pages) (Page 1 of 8 Pages) - ------------------ 1 The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, SEE the NOTES). - ---------------------------------- ----------------------------------- CUSIP NO. 671040 10 3 13D Page 2 of 8 Pages - ---------------------------------- ----------------------------------- - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS BIOTECHNOLOGY VALUE FUND, L.P. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/ (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - -------------------------------------------------------------------------------- NUMBER 7 SOLE VOTING POWER OF -0- SHARES -------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY 831,853 REPORTING -------------------------------------------- PERSON 9 SOLE DISPOSITIVE POWER WITH -0- -------------------------------------------- 10 SHARED DISPOSITIVE POWER 831,853 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 831,853 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES* / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 3.9% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* PN - -------------------------------------------------------------------------------- * SEE INSTRUCTIONS BEFORE FILLING OUT! - ---------------------------------- ----------------------------------- CUSIP NO. 671040 10 3 13D Page 3 of 8 Pages - ---------------------------------- ----------------------------------- - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS BVF PARTNERS L.P. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/ (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* OO - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - -------------------------------------------------------------------------------- NUMBER 7 SOLE VOTING POWER OF -0- SHARES -------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY 1,821,490 REPORTING -------------------------------------------- PERSON 9 SOLE DISPOSITIVE POWER WITH -0- -------------------------------------------- 10 SHARED DISPOSITIVE POWER 1,821,490 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,821,490 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES* / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 8.5% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* PN - -------------------------------------------------------------------------------- * SEE INSTRUCTIONS BEFORE FILLING OUT! - ---------------------------------- ----------------------------------- CUSIP NO. 671040 10 3 13D Page 4 of 8 Pages - ---------------------------------- ----------------------------------- - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS BVF INC. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/ (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC, OO - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - -------------------------------------------------------------------------------- NUMBER 7 SOLE VOTING POWER OF -0- SHARES -------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY 1,821,490 REPORTING -------------------------------------------- PERSON 9 SOLE DISPOSITIVE POWER WITH -0- -------------------------------------------- 10 SHARED DISPOSITIVE POWER 1,821,490 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,821,490 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES* / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 8.5% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* IA, CO - -------------------------------------------------------------------------------- * SEE INSTRUCTIONS BEFORE FILLING OUT! - ---------------------------------- ----------------------------------- CUSIP NO. 671040 10 3 13D Page 5 of 8 Pages - ---------------------------------- ----------------------------------- ITEM 1. SECURITY AND ISSUER. This Statement on Schedule 13D (this "Statement") relates to the Common Stock, par value $.01 per share (the "Stock"), of OSI Pharmaceuticals, Inc., a Delaware corporation ("OSI"). The principal executive office of OSI is located at 106 Charles Lindbergh Boulevard, Uniondale, NY 11553. ITEM 2. IDENTITY AND BACKGROUND. The persons filing this Statement, the persons enumerated in Instruction C of Schedule 13D and, where applicable, their respective places of organization, general partners, directors, executive officers and controlling persons, and certain information regarding each of them, are as follows: (a) Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF"), BVF Partners L.P., a Delaware limited partnership ("Partners"), BVF Inc., a Delaware corporation ("BVF Inc."), and Mark N. Lampert, an individual ("Lampert") (collectively, the "Reporting Persons"). (b) The business address of BVF and Partners is 333 West Wacker Drive, Suite 1600, Chicago, Illinois 60606. The business address of BVF Inc. and Lampert is One Sansome Street, 39th Floor, San Francisco, California 94104. (c) Partners is the general partner of BVF, which is an investment limited partnership. BVF Inc. is an investment adviser to and general partner of Partners. Lampert is the sole shareholder, sole director and an officer of BVF Inc. (d) During the last five years, none of such persons has been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors). (e) During the last five years, none of such persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) Lampert is a citizen of the United States of America. - ---------------------------------- ----------------------------------- CUSIP NO. 671040 10 3 13D Page 6 of 8 Pages - ---------------------------------- ----------------------------------- ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. Since July 6, 1998, Partners, in its capacity as general partner of BVF, has purchased on behalf of such limited partnership an aggregate number of 114,700 shares of the Stock for an aggregate consideration of $490,484.15, utilizing funds provided by BVF from its working capital pursuant to the terms of its limited partnership agreement with Partners. In addition, Partners, in its capacity as investment manager with respect to certain managed accounts, has purchased on behalf of such managed accounts an aggregate number of 218,300 shares of the Stock for an aggregate consideration of $1,017,029.56, utilizing funds under management by Partners pursuant to investment manager agreements between Partners and such managed accounts. ITEM 4. PURPOSE OF TRANSACTIONS. The external environment for small, quality biotechnology companies is undergoing a period of rapid and profound change. The convergence of a depressed equity market, the possible slowing pace of a corporate partnering activity, and escalating cash burn rates could produce an industry shake-out in which financially conservative companies prosper and financially weak companies falter. This changing environment may call for managements and Boards to husband capital by significantly reducing cash burn rates and to otherwise alter preconceived business plans. If managed pro-actively and intelligently, this period could yield attractive returns for shareholders. However, the consequences of complacency and the potential for irreparable missteps are great. BVF may seek to work with company managements, Boards and shareholders to maximize shareholder value and, specifically, to protect the substantial value of funded, partnered programs from unnecessary dilution. BVF IS AMENDING ALL ITS 13-D FILINGS WITH THIS NOTICE. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. (a) BVF beneficially owns 831,853 shares of the Stock, Partners beneficially owns 1,821,490 shares of the Stock, and BVF Inc. beneficially owns 1,821,490 shares of the Stock, approximately 3.9%, 8.5% and 8.5%, respectively, of the aggregate number of shares outstanding as of July 31, 1998 (as reported in OSI's most recent quarterly statement on Form 10-Q). (b) BVF shares voting and dispositive power over the 831,853 shares of the Stock it beneficially owns with Partners. Partners and BVF Inc. share voting and dispositive power over the 1,821,490 shares of the Stock they beneficially own with, in addition to BVF, the managed accounts on whose behalf Partners, as investment manager, purchased such shares. The managed accounts on whose behalf Partners owns shares of the Stock are Investment 10 L.L.C., an Illinois limited liability company ("ILL10") and Biotechnology Value Fund, Ltd., a Cayman Islands Corporation ("BVF Ltd."). ILL10 and BVF Ltd. are collectively referred to herein as the "Accounts." The Accounts specialize in holding biotechnology stocks for - ---------------------------------- ----------------------------------- CUSIP NO. 671040 10 3 13D Page 7 of 8 Pages - ---------------------------------- ----------------------------------- investment purposes and the business address of each is c/o BVF Partners L.P., 333 West Wacker Drive, Suite 1600, Chicago, Illinois 60606. (c) Exhibit B attached hereto contains information as to all transactions in the Stock by the Reporting Persons during the past 60 days. All such transactions were made for cash in open market, over-the-counter transactions. No other transactions in the Stock have been effected by the Reporting Persons during the past 60 days. (d) The Accounts are entitled to receive dividends and any sale proceeds with respect to the Stock in proportion to their respective ownership interests therein. ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER. Partners is the general partner of BVF pursuant to a limited partnership agreement which authorizes Partners, among other things, to invest the funds of BVF in the Stock and to vote and dispose of the Stock. Pursuant to such limited partnership agreement, Partners is entitled to allocations based on assets under management and realized and unrealized gains thereon. Pursuant to investment management agreements with the Accounts, Partners and BVF Inc. have the authority, among other things, to invest funds of the Accounts in the Stock and to vote and dispose of the Stock. Pursuant to such agreements, Partners and BVF Inc. receive fees based on assets under management and realized and unrealized gains thereon. BVF Inc. is the general partner of Partners and may be deemed to own beneficially securities over which Partners exercises voting and dispositive power. ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. Exhibit A - Agreement Regarding Joint Filing Exhibit B - Transactions in the Stock by the Reporting Persons during the past 60 days. - ---------------------------------- ----------------------------------- CUSIP NO. 671040 10 3 13D Page 8 of 8 Pages - ---------------------------------- ----------------------------------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: September 8, 1998 BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert ----------------------- Mark N. Lampert President BVF PARTNERS L.P. By: BVF Inc., its general partner By: /s/ Mark N. Lampert --------------------------------- Mark N. Lampert President BVF INC. By: /s/ Mark N. Lampert ------------------------------------------- Mark N. Lampert President EXHIBIT A AGREEMENT REGARDING JOINT FILING The undersigned, Biotechnology Value Fund, L.P., a Delaware limited partnership, and BVF Partners L.P., a Delaware limited partnership, and BVF Inc., a Delaware corporation, hereby agree and acknowledge that the statement containing the information required by Schedule 13D, to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any amendments or supplements thereto shall also be filed on behalf of each of them. Dated: September 8, 1998 BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert ----------------------- Mark N. Lampert President BVF PARTNERS L.P. By: BVF Inc., its general partner By: /s/ Mark N. Lampert --------------------------------- Mark N. Lampert President BVF INC. By: /s/ Mark N. Lampert ------------------------------------------- Mark N. Lampert President EXHIBIT B TRANSACTIONS IN THE STOCK BY THE REPORTING PERSONS DURING THE PAST 60 DAYS
- --------------------------------------------------------------------------------------------------- Settlement For the Price per Date By Account of Quantity Share Type of Trade Broker - --------------------------------------------------------------------------------------------------- - --------------------------------------------------------------------------------------------------- 07/08/98 Partners BVF Ltd. 5,200 $5.6250 Purchase INET - --------------------------------------------------------------------------------------------------- 07/10/98 Partners PAL 1,000 $5.2500 Purchase INET - --------------------------------------------------------------------------------------------------- 07/10/98 Partners ZPG 1,000 $5.2500 Purchase INET - --------------------------------------------------------------------------------------------------- 07/10/98 Partners BVF Ltd. 3,000 $5.2500 Purchase INET - --------------------------------------------------------------------------------------------------- 07/13/98 Partners BVF Ltd. 3,400 $5.1434 Purchase INET - --------------------------------------------------------------------------------------------------- 07/13/98 Partners BVF Ltd. 20,000 $5.2500 Purchase INET - --------------------------------------------------------------------------------------------------- 07/21/98 Partners ZPG 2,000 $5.3750 Purchase INET - --------------------------------------------------------------------------------------------------- 07/21/98 Partners BVF Ltd. 14,000 $5.3750 Purchase INET - --------------------------------------------------------------------------------------------------- 07/23/98 Partners BVF 26,600 $4.9911 Purchase INET - --------------------------------------------------------------------------------------------------- 07/23/98 Partners PAL 5,000 $4.9911 Purchase INET - --------------------------------------------------------------------------------------------------- 07/23/98 Partners ZPG 5,000 $4.9911 Purchase INET - --------------------------------------------------------------------------------------------------- 07/23/98 Partners BVF Ltd. 65,000 $4.9911 Purchase INET - --------------------------------------------------------------------------------------------------- 07/24/98 Partners BVF 4,600 $4.9375 Purchase INET - --------------------------------------------------------------------------------------------------- 07/24/98 Partners BVF Ltd. 4,000 $4.9375 Purchase INET - --------------------------------------------------------------------------------------------------- 07/27/98 Partners BVF Ltd. 2,300 $4.8750 Purchase INET - --------------------------------------------------------------------------------------------------- 07/27/98 Partners ILL10 400 $4.8750 Purchase INET - --------------------------------------------------------------------------------------------------- 07/27/98 Partners BVF 2,300 $4.8750 Purchase INET - --------------------------------------------------------------------------------------------------- 07/30/98 Partners BVF 2,500 $4.6250 Purchase INET - --------------------------------------------------------------------------------------------------- 07/30/98 Partners BVF Ltd. 2,000 $4.6250 Purchase INET - --------------------------------------------------------------------------------------------------- 08/04/98 Partners BVF 5,800 $4.2608 Purchase INET - --------------------------------------------------------------------------------------------------- 08/05/98 Partners BVF 10,000 $4.1250 Purchase INET - --------------------------------------------------------------------------------------------------- 08/05/98 Partners BVF Ltd. 10,000 $4.1250 Purchase INET - --------------------------------------------------------------------------------------------------- 08/06/98 Partners BVF Ltd. 16,000 $3.8750 Purchase VECT - --------------------------------------------------------------------------------------------------- 08/06/98 Partners ILL10 5,000 $3.8750 Purchase VECT - --------------------------------------------------------------------------------------------------- 08/06/98 Partners PAL 1,600 $3.8750 Purchase VECT - --------------------------------------------------------------------------------------------------- 08/06/98 Partners ZPG 1,400 $3.8750 Purchase VECT - --------------------------------------------------------------------------------------------------- 08/06/98 Partners BVF 16,000 $3.8750 Purchase VECT - ---------------------------------------------------------------------------------------------------
- --------------------------------------------------------------------------------------------------- Settlement For the Price per Date By Account of Quantity Share Type of Trade Broker - --------------------------------------------------------------------------------------------------- - --------------------------------------------------------------------------------------------------- 08/06/98 Partners BVF 11,900 $4.0625 Purchase INET - --------------------------------------------------------------------------------------------------- 08/06/98 Partners BVF Ltd. 10,000 $4.0625 Purchase INET - --------------------------------------------------------------------------------------------------- 08/06/98 Partners BVF 12,000 $3.8750 Purchase COWN - --------------------------------------------------------------------------------------------------- 08/06/98 Partners ILL10 1,000 $3.8750 Purchase COWN - --------------------------------------------------------------------------------------------------- 08/06/98 Partners PAL 1,000 $3.8750 Purchase COWN - --------------------------------------------------------------------------------------------------- 08/06/98 Partners ZPG 1,000 $3.8750 Purchase COWN - --------------------------------------------------------------------------------------------------- 08/06/98 Partners BVF Ltd. 10,000 $3.8750 Purchase COWN - --------------------------------------------------------------------------------------------------- 08/10/98 Partners BVF 22,000 $3.8125 Purchase INET - --------------------------------------------------------------------------------------------------- 08/10/98 Partners ILL10 4,000 $3.8125 Purchase INET - --------------------------------------------------------------------------------------------------- 08/10/98 Partners BVF Ltd. 24,000 $3.8125 Purchase INET - --------------------------------------------------------------------------------------------------- 09/02/98 Partners BVF 1,000 $3.6250 Purchase INET - ---------------------------------------------------------------------------------------------------
COWN = Cowen & Co. INET = Instinet VECT = Vector Securities -----END PRIVACY-ENHANCED MESSAGE-----